NCT06996782 · AstraZeneca
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
(ALTAIR)
What this study is about
The purpose of this study is to assess the safety and effectiveness of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
View original scientific description
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- (both sub study 1 and sub study 2):
- Participants with confirmed squamous or non-squamous NSCLC with a current Stage IV mNSCLC.
- Provision of acceptable archival tumour tissue (or fresh tumour tissue biopsy if archival tumour tissue is not available and if clinically feasible) is mandatory at screening.
- Measurable disease as defined by at least one lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter.
- Minimum life expectancy of 12 weeks in the opinion of the investigator.
- Adequate organ and marrow function.
- Contraceptive use by male or female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Adequate organ and marrow function and minimum body weight of 30 Kg.
- PD-L1 tumour proportion score (TPS) ≥ 1% (per local report). Inclusion Criteria for Sub Study 2: \- Adequate coagulation and urinalysis.
Exclusion criteria
- (both sub study
Where
- Phoenix, Arizona
- Santa Rosa, California
- Jacksonville, Florida
- Baltimore, Maryland
- Detroit, Michigan
- Rochester, Minnesota
- Cleveland, Ohio
- Providence, Rhode Island
- Tyler, Texas
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 17, 2026 · Source of record for eligibility and locations